CDSCO To Accept Pre-Clinical Toxicity Data Generated In Other Countries Subject To Conditions

New Delhi: The Central drug regulator, the Central Drugs Standard Control Organisation (CDSCO) has decided to accept the preclinical toxicity data already generated and accepted by regulatory authorities of other countries for review of new drugs, subsequent new drugs (SNDs) and fixed dose combinations (FDCs), subject to certain conditions.

In a latest circular issued to the industry, the Drugs Controller General (India) (DCGI) Dr Rajeev Singh Raghuvanshi said that the CDSCO has reviewed the requirement of toxicity studies for new drugs, SNDs and FDCs, excluding biological products and Investigational New Drugs (INDs).

According to the New Drugs and Clinical Trials Rules, 2019, the regulator noted that, a repeated dose toxicity study in India may not be mandatory in certain cases including when a data on animal toxicity as per the specifications in the rule, has been submitted and the same has been considered by the regulatory authority of the country which had earlier approved the drug.

The animal toxicity data generated in other countries may be accepted and may not be asked to be repeated in India on a case to case basis depending upon the quality of data and the credentials of the laboratory where such data has been generated, noted the regulator pointing to the Schedules of the NDCG Rules, 2019.

“In view of the above, it has been decided to accept already generated preclinical toxicity data for review in the case of drug substance and drug product, based on the quality of data and the credentials of the laboratory where such data has been generated,” said the DCGI

However, the animal toxicity data needed in certain cases such as new claims namely, indications, dosage, dosage form or route of administration etc., should be determined on case by case basis depending on the nature of new claims as well as the mechanism of action etc., and the non-clinical data already generated with the drug in the approved claim, added the drug regulator.

Use of unapproved excipients in the formulation also will require relevant safety data.

Besides, as per the NDCT Rules, 2019, sub-acute animal toxicity studies for intravenous infusions and injectables data is still required to be submitted by an applicant for grant of permission to import or manufacture such new drug as mentioned in the Second Schedule of the Rules, added the drug regulator.

Related Posts

  • Pharma
  • December 6, 2024
  • 89 views
Surat Police Nab 13 Bogus Doctors In Fake Degree Scam

Surat:  The Surat Zone-4 Police today arrested 13 bogus doctors who were practicing medicine with fake medical degrees in the city. The main accused, Rasesh Gujarati, has also been arrested…

  • Pharma
  • December 6, 2024
  • 95 views
Maternal Death Toll In Ballari Hospital Touches Five After One More Woman Dies

Bengaluru:  Sumayya, a resident of Kudligi was admitted to the hospital on 11 November, and she underwent a caesarian section the same day. However, she developed complications and was shifted…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Surat Police Nab 13 Bogus Doctors In Fake Degree Scam

Surat Police Nab 13 Bogus Doctors In Fake Degree Scam

FDA Approves New Drug For Lung And Pancreatic Cancers

FDA Approves New Drug For Lung And Pancreatic Cancers

Maternal Death Toll In Ballari Hospital Touches Five After One More Woman Dies

Maternal Death Toll In Ballari Hospital Touches Five After One More Woman Dies

Tumakuru Police Seize 1,700 Tapentadol Tablets Sold Over The Counter

Tumakuru Police Seize 1,700 Tapentadol Tablets Sold Over The Counter

Shortage Of Doctors, No Valid Licences For Blood Banks,’ Says CAG Report

Shortage Of Doctors, No Valid Licences For Blood Banks,’ Says CAG Report

Tafenoquine Single-Dose Medicine For P. Vivax Malaria Prequalified By WHO And Included In WHO Guidelines

Tafenoquine Single-Dose Medicine For P. Vivax Malaria Prequalified By WHO And Included In WHO Guidelines